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Background: Globally, breast cancer is the most frequent cancer among women. 
Studies reported an increased risk of breast cancer among women with prior cervical 
dysplasia. This study aimed to describe the prevalence of human papillomavirus (HPV) in 
breast cancer and explore if women with prior cervical neoplasia carry an increased risk 
of HPV-positive breast cancer compared to women without.
Methods: This case–control study identified 193 Danish women diagnosed with breast 
cancer (1998–2012) at Aarhus University Hospital or Copenhagen University Hospital 
Herlev. Cases were 93 women with cervical intraepithelial neoplasia grade 3 or worse 
(CIN3+) prior to breast cancer. Controls were 100 women without prior cervical dys-
plasia. HPV testing and genotyping were done using SPF10 PCR-DEIA-LiPA25 and an 
in-house semi-Q-PCR assay.
results: Overall HPV prevalence in breast cancer for the assays was 1.55% (95% 
CI 0.32–4.48) and 0.52% (95% CI 0.01–2.85). There was no difference in HPV prevalence 
between cases and controls (2.15 vs. 1.00%, p = 0.61 and 1.08 vs. 0.00%, p = 0.48). 
HPV prevalence in CIN3+ was 94.62% (95% CI 0.88–0.98). Concordance between the 
assays was 98.60%.
conclusion: HPV prevalence in breast cancer is very low suggesting no etiological 
correlation between HPV and breast cancer.
Keywords: breast cancer, hPV, cervical cancer, polymerase chain reaction, Denmark, pathology, human papillomavirus
inTrODUcTiOn
Human papillomavirus (HPV) has been established as the leading cause of cervical cancer (1), and 
the virus is known to also play a causative role in anal, penile, vulvar, and presumably also head 
and neck cancer (2). In the past decades, an increase in the incidence of HPV-related cancers has 
been observed (3–5). HPV is a double-stranded circular DNA virus that replicates in the nucleus of 
mucosal or cutaneous keratinocytes (6) and so far, over 170 HPV genotypes have been identified. 
FigUre 1 | Flowchart of included women.
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Based on carcinogenic risk, these can be classified as high-risk 
(HR), probably HR, or low-risk (LR) HPV genotypes (7).
Breast cancer accounts for 25% of cancer cases and 15% of 
cancer-related deaths among women worldwide (8). As a result 
of the increasing incidence of HPV-related cancers over time and 
the 30% increase in breast cancer incidence in western countries 
between 1980 and the late 1990s (8), recent studies have suggested 
a possible association between HPV and breast cancer. Hansen 
et  al. (9) found that the standardized incidence ratios (SIRs) 
of breast cancer during 1970–2008 were significantly higher 
in women with a previous diagnosis of squamous or glandular 
cervical dysplasia compared to the general female population 
(SIR, 95% CI for squamous 1.10, 1.05–1.14, for glandular 1.52, 
1.11–2.08). Data from Søgaard et al. (10) are less convincing. By 
using conization as a marker of persistent HPV infection, they 
showed that conization was associated with a slightly increased 
breast cancer incidence (SIR, 95% CI 1.10, 1.0–1.1). Nevertheless, 
several studies suggest that breast cancer in some cases may 
be initiated by HPV (11–17), whereas other studies disagree 
(18–20). Due to this discrepancy in the results, we found it is 
important to explore a possible association between HPV and 
breast cancer. Thus, in the present study, we aimed to describe 
the overall prevalence of HPV in breast cancer in Denmark and to 
explore if women with a previous history of cervical intraepithe-
lial neoplasia grade 3 or worse (CIN3+) carry an increased risk 
of subsequent HPV-positive breast cancer compared to women 
with no history.
MaTerials anD MeThODs
setting
We conducted a hospital-based case–control study in Denmark, 
where all patients have access to the health care system at no 
cost. Upon birth or immigration, each Danish citizen is assigned 
a CPR-number, which is a unique code that reflects the person’s 
age, sex, and the date of birth. Estimates in this study are based 
upon women who were diagnosed with breast cancer during 
1998–2012 at Aarhus University Hospital and Copenhagen 
University Hospital Herlev.
Data collection
The Danish Pathology Data Bank (DPDB) is a national data-
bank storing results on all patho-anatomical tests conducted 
in Denmark, and it used the Systematized Nomenclature of 
Medicine (SNOMED) as nomenclature and classification system.
The study population was identified through two SNOMED 
searches in the DPDB (Figure  1). A complete list of topogra-
phy and morphology codes used in these searches is provided 
in the supplementary material (Supplementary Data S1 in 
Supplementary Material). The first search was used to define 
an overall study group of women who had been diagnosed with 
breast cancer during 1998–2012 at the two above-mentioned 
Danish hospitals. Women were eligible if they had a histologically 
verified diagnosis of breast cancer (i.e., ductal carcinoma, lobular 
TaBle 1 | Characteristics of the study population (N = 193).
Patients case subjects,
N = 93
control subjects,
N = 100
Breast cancer n(%, 95% ci) n(%, 95% ci)
age (years)
30–39 11 (11.83, 21.50–22.85) 9 (9.00, 0.00–19.36)
40–49 34 (36.56, 26.88–47.58) 37 (37.00, 27.00–47.36)
50–59 26 (27.96, 18.28–38.98) 36 (36.00, 26.00–46.36)
60–69 15 (16.13, 64.52–27.15) 17 (17.00, 7.00–27.36)
70+ 7 (7.53, 0.00–18.55) 1 (1.00, 0.00–1.36)
histologic type
Ductal carcinoma 80 (86.02, 80.65–93.30) 84 (84.00, 78.00–91.42)
Lobular carcinoma 10 (10.75, 4.30–17.32) 16 (16.00, 10.00–23.42)
Combined ductal/
lobular carcinoma
2 (2.15, 0.00–8.72)
Metaplastic carcinoma 1 (1.08, 0.00–7.64)
Year at diagnosis n (%) n (%)
1998–2000 4 (4.30) 19 (19.00)
2001–2003 10 (10.75) 22 (22.00)
2004–2006 17 (18.28) 21 (21.00)
2007–2009 31 (33.33) 17 (17.00)
2010–2012 31 (33.33) 21 (21.00)
cin3+ n (%, 95% ci)
age (years)
<30 4 (4.30, 0.00–15.52)
30–39 27 (29.03, 19.35–40.25)
40–49 24 (25.80, 16.13–37.02)
50–59 25 (26.88, 17.20–38.10)
60+ 13 (13.98, 4.30–25.19)
histologic type
CIN3 34 (0.37, 0.27–0.48)
Squamous cell 
carcinoma in situ
31 (0.33, 0.24–0.45)
Adenocarcinoma in situ 3 (0.03, 0.00–0.15)
Squamous cell carcinoma 20 (0.22, 0.12–0.33)
Adenocarcinoma 5 (0.05, 0.00–0.17)
Year at diagnosis n (%)
1998–2000 28 (30.11)
2001–2003 30 (32.26)
2004–2006 18 (19.35)
2007–2009 12 (12.90)
2010–2012 5 (5.38)
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carcinoma, combined ductal/lobular carcinoma, or metaplastic 
carcinoma), regardless of stage. Women were ineligible if they 
had a known family history of breast and/or ovarian cancer 
suggesting BRCA1/BRCA2 mutation, or if they had been diag-
nosed with triple-negative breast cancer as this type is known to 
account for at least one-third of BRCA1 mutated tumors (21). 
Controls were selected randomly from the overall study group. 
The second search was used to identify an applicable group of 
women who had a previous diagnosis of CIN3+ in addition 
to their breast diagnosis (i.e., case group). For the purpose 
of this study, CIN3+ refers to cases of cervical intraepithelial 
neoplasia grade 3 or worse (i.e., CIN3, adenocarcinoma in situ, 
squamous cell carcinoma in situ, squamous cell carcinoma, or 
adenocarcinoma).
controls
Women in the control group were eligible if they had a record 
of at least two normal cervical cytology results within 5 years of 
their breast cancer diagnosis. Women were excluded if they had 
a previous record of cervical dysplasia or cervical cancer. Overall, 
100 women with a diagnosis of breast cancer were included in the 
control group (Table 1).
cases
Women in the case group were eligible if they had been diagnosed 
with CIN3+ prior to or no later than 18 months after their breast 
cancer diagnosis. The rationale behind this decision was that 
cases of cervical dysplasia diagnosed shortly after breast cancer 
most likely were present before, in particular given the known 
natural history of HPV-related disease. All CIN3+ cases were 
histologically verified, and if there was uncertainty about the 
origin of the cervical tumor (e.g., a diagnosis of endometrioid 
carcinoma or metastasis from breast cancer, ovarian cancer, or 
vulvar cancer), the case was excluded. A total of 93 women with 
a history of both CIN3+ and breast cancer were included in the 
case group (Table 1).
Tumor specimens and Quality control
Formalin-fixed paraffin-embedded tissue blocks (FFPE) contain-
ing CIN3+ tissue and breast cancer tissue were collected at the par-
ticipating pathology departments during May through November 
2016. All blocks were sectioned at the Department of Pathology, 
Aarhus University Hospital. The sandwich technique was applied 
to ensure histopathological confirmation of tumor tissue in the 
sections flanking the sections subjected to HPV analysis. First, 
a 3-μm-thick section was cut for hematoxylin and eosin staining 
(HE). Second, four to eight 10-μm-thick sections were cut and 
subsequently macro-dissected to ensure that only the neoplastic 
area was dissected off the slide and collected in a sterile tube. To 
avoid contamination between specimens, gloves were changed 
before cutting each block, the knife was changed before cutting 
each tissue sample, and the microtome, tweezers, and brush were 
carefully cleaned with 1% sodium dodecyl sulfate and 99% etha-
nol before and after cutting every block. Furthermore, no paraffin 
block containing cervical tissue was cut on the microtome during 
the process of breast tissue sectioning. Finally, after collecting the 
tissue into tubes, a 3-μm-thick section was cut for HE staining. As 
quality control, both positive and negative controls were included 
and analyzed on the same terms as the CIN3+ and breast cancer 
samples. Negative controls were used to ensure no contamination 
of HPV from the persons performing the procedures, and they 
consisted of two components; tubes with sections from an FFPE 
block containing only pure paraffin (i.e., pure paraffin blocks) and 
tubes with purified material from cytolomegavirus embedded in 
paraffin. DNA extraction was performed at the Department of 
Pathology, Aarhus University Hospital using the QIAsymphony 
DSP DNA Mini Kit, version 1 (Qiagen, Venlo, the Netherlands).
hPV Detection
Human papillomavirus detection and genotyping of all samples 
were performed at two laboratories using two different PCR-based 
TaBle 2 | Characteristics of the PCR-based human papillomavirus (HPV) assays.
hPV detection 
method
hPV-genomic 
regions 
targeted by the 
primer sets
amplicon 
size
included controls hPV genotypes detected lODa
SPF10LiPA25 
(strip-based reverse 
hybridization)
L1 65 bp External: HPV 6, 11, 16, 18, 31, 33, 34, 35, 39, 
40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 
58, 59, 66, 68, 70, and 74
1:100.000b
SiHa cells
Pure paraffin samples
Cytolomegavirus (CMV) control
HPV 18 positive and HPV-negative PCR control
HPV-positive + borderline + negative DNA enzyme 
immunoassay control
Internal:
None
Semi-quantitative-
PCR (semi-Q-PCR)
E6/E7 82–134 bp External: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, and 59
Not measured
CMV control
Pure paraffin sample
HPV-positive control for the specific HPV genotype 
tested for in each Q-PCR
Internal:
Glyceraldehyde-3-phosphate dehydrogenase 
(DNA control) 
aLimit of detection.
bBased on dilutions of SiHA cell lines, which contain 1–2 HPV 16 copies per cell line.
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HPV assays that allow the detection of HPV DNA. Characteristics 
of the two assays are summarized in Table  2. HPV analyses 
performed in Aarhus were conducted using the SPF10 PCR-DEIA-
LiPA25 assay (version 1; Labo Biomedical Products, Rijswijk, The 
Netherlands) (SPF10LiPA25), which used the SPF10 primer set to 
amplify a 65 base pair (bp) region in the L1 open-reading frame. 
After PCR, HPV-positive samples were distinguished from 
HPV-negative using the DNA enzyme immunoassay (DEIA). 
HPV genotyping of HPV-positive samples were subsequently 
performed with a reverse hybridization technique (LiPA25) that 
allowed the detection of 25 HR and LR HPV genotypes (i.e., 6, 
11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 
58, 59, 66, 68, 70, and 74) (11). For the SPF10LiPA25 procedure, 
the positive controls consisted of HPV 16-infected SiHa cell lines 
embedded in paraffin.
In Herlev, analyses were carried out using a semi-quantitative 
PCR assay (semi-Q-PCR) based on Taqman probes (22, 23). 
This assay allowed the detection and genotyping of the HPV 
genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59. The 
semi-Q-PCR consisted of a real-time PCR (RT-PCR) targeting 
the E6/E7 region of the HPV genome. Primer and probes were 
chosen with specificity for the HPV genotypes 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, and 59, and the house holding gene glycer-
aldehyde-3-phosphate dehydrogenase was included as a positive 
DNA control. RT-PCRs were performed on the ABI 7500 FAST 
RT-PCR system. As a positive control, we used purified DNA 
from FFPE patient samples known to be positive for the specific 
HPV genotype subjected to analysis. Initially, PCR was designed 
to detect HPV 16 and 18, and this analysis was conducted on all 
286 breast and cervical samples. Subsequently, samples positive 
for other HPV types by the SPF10LiPA25 (i.e., both single and 
multiple infections) were chosen for blinded analyses of the HPV 
genotypes 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59.
All analyses were conducted according to the manufacturer’s 
instructions.
statistical Methods
The prevalence of HPV was calculated as the number of HPV-
positive samples divided by the total number of samples tested, 
whereas the genotype-specific prevalence was calculated as the 
number of samples positive for a given genotype with or without 
co-infection with other genotypes divided by the number of all 
samples tested. HPV test results obtained using the two assays 
were analytically compared at the level of general detection of the 
12 HPV genotypes included in both assays, as well as the level of 
individual genotype identification of HPV types. Fishers exact test 
was used on binary outcomes. The two-tailed McNemar’s test was 
used for mutual comparison of positivity rates by SPF10LiPA25 and 
semi-Q-PCR, and Cohen’s kappa statistic was used to determine 
the rate of agreement (Table 3). The level of statistical significance 
was set at 0.05. Analyses were carried out using R version 3.3.2 
(24) with the Multinomial CI-package (25). Results described are 
based on the results from both assays, and the matching figures 
are based on the results from the SPF10LiPA25 analyses.
resUlTs
Through DPDB, we identified a total of 23,837 women with a 
record of a breast cancer diagnosis during 1998–2012, of which 
we included 93 cases (i.e., women with a history of CIN3+ and 
breast cancer) and 100 controls (i.e., women with a history of 
breast cancer only) (Figure 1). Basic characteristics of cases and 
controls are summarized in Table 1.
There was no difference in mean age (±SD) at breast cancer 
diagnosis between cases [51.82  years (±11.48)] and controls 
[50.35 years (± 8.49)] and in both groups, ductal carcinoma was 
by far the most frequent breast cancer diagnosis (86.02%, 95% CI 
80.65–93.30 vs. 84.00%, 95% CI 78.00–91.00). In the case group, 
mean age at the time of CIN3+ diagnosis was 47.20 years (±11.95). 
The vast majority of cases had been diagnosed with CIN3+ prior 
TaBle 4 | Human papillomavirus (HPV) genotype distribution in breast cancer 
and CIN3+ tissue.
sPF10liPa25 semi-Q-Pcr
n (%) n (%)
cin3+ samples, N = 93
single infections
HPV 16 42 (45.16) 41 (44.09)
HPV 18 5 (5.38) 6 (6.45)
HPV 31 9 (9.68) 9 (9.68)
HPV 33 7 (7.53) 7 (7.53)
HPV 35 1 (1.08) 1 (1.08)
HPV 39 1 (1.08) 1 (1.08)
HPV 45 8 (8.60) 8 (8.60)
HPV 51 1 (1.08) 1 (1.08)
HPV 52 4 (4.30) 4 (4.30)
HPV 56 2 (2.15) 2 (2.15)
HPV 58 3 (3.23) 3 (3.23)
HPV 59 1 (1.08) 1 (1.08)
Multiple infections
HPV 18 + 31 1 (1.08) 1 (1.08)
HPV 45 + 52 1 (1.08) 1 (1.08)
HPV 33 + 31 1 (1.08) 1 (1.08)
HPV 58 + 45 1 (1.08) 1 (1.08)
HPV-negative 5 (5.38) 5 (5.38)
case group breast cancer, N = 93
single infections
HPV 16 1 (1.08) 1 (1.08)
HPV 56 1(1.08)
HPV-negative 91 (97.85) 92 (98.92)
control group breast cancer,  N = 100
single infections
HPV 16 1 (1.00) 0 (0.00)
HPV-negative 99 (99.00) 100 (100.00)
Total 286 286
TaBle 3 | Concordance in the 92 cervical and breast samples in which one of 
the assays detected one or two of the 12 human papillomavirus (HPV) genotypes 
detected.
sPF10liPa25 
(%a)
semi-Q-
Pcr (%a)
Kappa-value 
(95% ci)
Mc nemar’s
p-value
cin3+ samples
HPV 16 42 (45.65) 41 (44.57) 0.98 (0.94–1.02) 1
HPV 18 6 (6.52) 7 (7.61) 0.92 (0.76–1.08) 1
HPV 31 11 (11.96) 11 (11.96) 1 NAc
HPV 33 8 (8.70) 8 (8.70) 1 NAc
HPV 35 1 (1.09) 1 (1.09) – –
HPV 39 1 (1.09) 1 (1.09) – –
HPV 45 10 (10.87) 10 (10.87) 1 NA
HPV 51 1 (1.09) 1 (1.09) – –
HPV 52 5 (5.43) 5 (5.43) 1 NA
HPV 56 2 (2.17) 2 (2.17) 1 NA
HPV 58 4 (4.35) 4 (4.35) 1 NA
HPV 59 1 (1.09) 1 (1.09) – –
Total 92b 92b
Breast cancer samples
HPV 16 2 (66.67) 1 (100.00) – –
HPV 56 1 (33.33) 0 (0.00) – –
aGenotype-specific HPV prevalence: number of samples positive for a given genotype 
(with or without co-infection with other genotypes) divided by the number of all samples 
(92).
bSince some samples are positive for two HPV genotypes, the total number of HPV-
positive CIN3+ samples (92) is higher than the number of CIN3+ samples tested positive 
for HPV (88), see Table 4.
cComplete agreement.
–,Too few positive samples, testing not appropriate.
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to their breast cancer diagnosis (p < 0.0001) with a mean time 
from CIN3+ diagnosis to breast cancer diagnosis of 4.61 years 
(SD 95% CI 3.78–5.45) (Figure S1 in Supplementary Material). 
Most CIN3+ cases were CIN3 (37%, 95% CI 27.00–48.00) or 
squamous cell carcinoma in situ (33%, 95% CI 24–45) (Table 1).
hPV Prevalence
Overall prevalence of HPV in breast cancer was 0.52% (95% 
CI 0.32–4.48) when using semi-Q-PCR and 1.55% (95% 
CI 0.01–2.85) when using SPF10LiPA25. According to both assays, 
the HPV prevalence in breast cancer was not significantly differ-
ent in cases compared to controls (SPF10LiPA25: 2.15 vs. 1.00%, 
p = 0.61; semi-Q-PCR: 1.08 vs. 0.00%, p = 0.48) (Figure S2 in 
Supplementary Material). In the case group, two breast cancer 
samples were positive for HPV according to SPF10LiPA25 (2.15%); 
one was HPV 16 positive and one was HPV 56 positive. Both 
women had a CIN3+ specimen that was positive for HPV 58. 
The semi-Q-PCR assay found one HPV 16-positive breast cancer 
sample in the case group (1.08%), and this was the same sam-
ple, that was HPV 16 positive with SPF10LiPA25. In the control 
group, one breast cancer sample was positive for HPV 16 (1.00%) 
according to SPF10LiPA25, and none tested positive for HPV 
(0.00%) according to the semi-Q-PCR.
The prevalence of HPV in CIN3+ was 94.62% (95% CI 
87.90–98.23) in both the SPF10LiPA25 and the semi-Q-PCR 
analyses (Figure S2 in Supplementary Material), and HPV 16 
was the most commonly detected genotype (45.16 vs. 44.09%) 
followed by HPV 31 (11.96 vs. 11.96%) (Table  3; Figure S3 in 
Supplementary Material).
genotyping agreement
The HPV genotyping results of CIN3+ tissue and breast cancer 
tissue are summarized in Table  4. SPF10LiPA25 analyses were 
HPV-negative in 195 (68.18%, 95% CI 62.44–73.54) samples 
and HPV-positive in 91 (29.37%, 95% CI 26.46–37.56) samples, 
whereas the semi-Q-PCR analyses were HPV-negative in 197 
(68.88%, 95% CI 63.13–74.20) samples and HPV-positive in 89 
(31.12%, 95% CI 25.80–36.84) samples. Among the 92 cervical 
and breast samples that tested positive for HPV with one of the 
assays, SPF10LiPA25 detected one HPV genotype in 87 (94.57%) 
samples, two types in four (4.35%) samples, and no HPV in 
one (1.09%) sample. Using the semi-Q-PCR, one type was 
detected in 85 (92.39%) of these 92 samples, two types in four 
(4.35%) samples, and no HPV in one (1.09%) sample (Table 3). 
For both assays, the negative and positive controls tested negative 
and positive for HPV, respectively.
Genotyping results by both assays showed that 282 (98.60%) 
were concordant and four (1.40%) were discordant (Table  4). 
6Bønløkke et al. HPV and Breast Cancer
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Table 3 shows the concordance between the CIN3+ and breast 
cancer samples that tested positive for one or two HPV genotypes 
by either the SPF10LiPA25 or semi-Q-PCR. The assays demon-
strated high agreement rates in general HPV detection, which 
can be seen from the comparison of agreement rates ranging from 
0.92 to 1.00.
DiscUssiOn
In this study, overall HPV prevalence was <2% in breast cancer 
and 94.62% (95% CI 87.90–98.23) in CIN3+. All samples were 
tested using two highly sensitive PCR-based HPV assays, and the 
agreement rate between them was high with an overall concord-
ance of 98.60%.
For some years, it has been suggested that HPV, in addition 
to causing cervical cancer, may also play a role in breast cancer 
carcinogenesis (9, 11–17, 26). Several studies found that a 
considerable amount of breast cancers (i.e., 12.90–86.20%) are 
positive for HR-HPV (17, 24, 27–31). Other studies reported the 
detection of HPV in sera and axillary lymph nodes from breast 
cancer patients (11–14) indicating a haematogenic spread of 
the virus. However, other studies (18, 19, 32) have reported a 
very low prevalence of HPV (0–5.70%), which is in agreement 
with the findings in our study. The difference in HPV positivity 
between studies may partly be explained by differences in the 
HPV detection assay used. Thus, the sensitivity of target ampli-
fications methods is higher compared to signal amplification 
methods. One study (19) used the same assay as the present study 
(i.e., SPF10LiPA25) and reported no HPV-positive breast cancer 
cases among 76 cases tested. The difference in HPV prevalence 
across studies may also be explained by false positive results, where 
contamination is a crucial point. Studies have shown that HPV 
can be detected in up to 18% of samples obtained from fomites 
in an gynecological outpatient clinic (33) and that DNA particles 
deposited on environmental surfaces may stay infectious for up 
to 7 days after desiccation (34, 35). Thus, studies on HPV must 
have an immense focus on contamination control. Some of the 
previous studies reporting high HPV prevalence rates in breast 
cancer tissue have not reported the use of contamination control 
(12, 14, 16, 17), and the high HPV prevalence may, therefore, be 
due to contamination, at least partly. This is furthermore sup-
ported by the fact that some studies not only report high HPV 
prevalence rates in breast cancers but also in their control samples 
from benign breast biopsies (17, 36). As already described in the 
methods, the present study had a very strict procedure in terms 
of contamination control, and according to our results there was 
no sign of contamination. Thus, the fact that our study results is in 
agreement with some of the previous studies (18, 19, 32) is likely 
due to similarities between the studies in terms of contamination 
control.
Other reasons for the disagreement between studies may be 
due to differences in the cases selected for analysis. Thus, some 
studies have included cases of ductal carcinoma in situ (DCIS) in 
addition to invasive breast cancer cases, whereas others included 
benign tumors. However, if HPV is hypothesized to play a role 
in breast cancer carcinogenesis, it seems reasonable to assume 
that DCIS cases as well as benign tumors would, at least to some 
extent, turn out to be HPV-positive with rising prevalence rates 
with increasing severity of the disease similar to what is observed 
in precancers and cancers of the cervix. The prevalence of HPV is 
known to be positively correlated with the severity of the cervical 
disease (37), which means that the prevalence of HPV is higher in 
CIN3 compared to CIN1. This specific matter, together with the 
hypothesis that high-grade cervical lesions would presumably be 
more likely to have viral spread than low-grade lesions, explains 
why this study included only patients who had previously been 
diagnosed with CIN3+, whereas some studies have included 
women with a previous diagnosis of low-grade dysplasia in the 
case group (9, 15).
Furthermore, we acknowledge the risk of false-negative results 
when using old FFPE tissue, in particular due to possible DNA 
degradation and cross-linking (38), and thus, we cannot rule out 
that the prevalence of HPV would have been higher if we had 
included fresh samples or samples from a recent time period 
only. In the present study, the included samples had been stored 
for 5–19 years. However, our study used highly sensitive PCR-
based HPV assays generating short amplicons and moreover, our 
analyses on cervical case samples showed a high HPV-positivity 
rate in both recent and older samples.
Some studies have suggested that the viral load of HPV in 
breast cancer is far lower than 1 copy/cell (20, 39), suggesting 
that the low prevalence in some studies is simply a result of a low 
sensitivity. Since our study used two very sensitive PCR-based 
assays and furthermore included a sensitivity analysis of the 
SPF10LiPA25, which revealed that it was possible to detect HPV 16 
at very low concentrations (i.e., 1:100.000, see Table 2), we find 
it less likely that HPV-positive breast cancers have been missed. 
Additionally, if HPV was in fact causally related to breast cancer, 
it seems reasonable to assume that the viral load would be higher 
and thus easy to detect.
Contrary to the results from this study, previous studies have 
reported that women with a record of previous cervical dysplasia 
have a significantly higher risk of subsequent breast cancer than 
women without (9, 10). Since we found no association between 
HPV and breast cancer, this finding may be a result of an inef-
ficient immune system as women with dysplasia have already 
shown that their immune system is incapable of clearing an infec-
tion, or it may be due to common risk factors for carcinogenesis 
of the breast and the cervix such as smoking. Another plausible 
explanation argued by some studies is that it may reflect differ-
ences in the expression of specific genes (40–43) and which may 
be regulated by HPV (44–46). However, results from the present 
study do not support this hypothesis.
In Denmark, each Danish citizen is assigned a unique CPR-
number that reflects the person’s age, sex, and the date of birth, 
and Danish registries are based on precisely this number, which 
makes them very valid. The present study used the DPDB to 
identify relevant study subjects, and the risk of selection bias was, 
therefore, minimal. Besides minimizing the risk of selection bias, 
the use of two highly sensitive PCR-based HPV assays ensured a 
high sensitivity and reduced the risk of false negative results. The 
SPF10LiPA25 utilizes the SPF10 primers, which amplify a 65  bp 
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region in the L1 open-reading frame, whereas the semi-Q-PCR 
utilizes type-specific primers targeting the E6 and E7 region of 
HPV genome. The SPF10LiPA25 is known as one of the most suit-
able for HPV genotyping, especially in FFPE specimens due to its 
very high analytical sensitivity (47). However, other studies have 
reported higher detection rates when using primers targeting E6 
and/or E7 (38). In contrast to L1, E6 and E7 areas are usually 
maintained during HPV-DNA integration, and consequently, 
assays utilizing primers targeting E6 and E7 have been reported 
to have high detection rates (38). Nevertheless, only four samples 
showed discordant results, corresponding to a 98.60% concord-
ance rate between the two assays.
This study has some limitations that must be addressed. First, 
all samples were analyzed by SPF10LiPA25 and subsequently tested 
for HPV 16 and 18 using the semi-Q-PCR. Only samples that 
tested positive for other HPV types by the SPF10LiPA25 (i.e., single 
and multiple infections) were chosen for blinded analysis of the 
HPV genotypes 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 using the 
semi-Q-PCR. We, therefore, cannot rule out an underestimation 
of the overall prevalence and the prevalence of multi-infections 
when using the semi-Q-PCR. This may also have biased the 
concordance rate between the two assays toward a higher agree-
ment rate. Second, we cannot exclude that selection bias may 
have occurred. We chose not to include cases considered at HR 
of being a BRCA-mutated breast cancer (e.g., triple-negative 
breast cancer) as we hypothesized that these cancers occur due 
to somatic mutations and not as a result of an HPV infection. 
However, we cannot know if the HPV prevalence would have 
been higher had we included these cancers as well. Unlike many 
other countries where population-based registries do not exist, 
we were able to retrieve the screening history of the entire study 
population at the individual level making this case–control 
study of high quality. However, we cannot preclude that some 
women in the control group may have had dysplasia prior to the 
establishment of the DPDB (i.e., 1998) although most pathology 
departments have transferred data. Nevertheless, because the 
overall HPV prevalence in breast cancer was very low and only a 
minority of women would have been eligible for screening before 
1998, we find this less likely to affect our results.
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